Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
22.17
+0.04 (0.18%)
At close: Mar 6, 2026, 4:00 PM EST
22.22
+0.05 (0.23%)
After-hours: Mar 6, 2026, 7:59 PM EST
Neurogene Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Neurogene stock have an average target of 60.13, with a low estimate of 16 and a high estimate of 200. The average target predicts an increase of 171.22% from the current stock price of 22.17.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Neurogene stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 4 | 4 |
| Buy | 3 | 2 | 2 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 6 | 6 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $200 | Strong Buy | Initiates | $200 | +802.12% | Feb 27, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Initiates $50 | Buy | Initiates | $50 | +125.53% | Jan 26, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $70 | Strong Buy | Reiterates | $70 | +215.74% | Jan 13, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $65 → $70 | Strong Buy | Maintains | $65 → $70 | +215.74% | Nov 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $45 → $65 | Strong Buy | Maintains | $45 → $65 | +193.19% | Oct 31, 2025 |
Financial Forecast
Revenue This Year
n/a
from 925.00K
Revenue Next Year
n/a
EPS This Year
-4.28
from -4.28
EPS Next Year
-5.31
from -4.28
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -4.33 | -4.56 | |||
| Avg | -4.28 | -5.31 | |||
| Low | -4.18 | -6.36 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.